Inventiva
FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares
FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune
Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor
Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical